511 related articles for article (PubMed ID: 30811784)
21. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
[TBL] [Abstract][Full Text] [Related]
22. Complete Transurethral Resection before Radical Cystectomy May Improve Oncological Outcomes.
Graffeille V; Verhoest G; Gryn A; Kammerer-Jacquet SF; Alimi Q; Beauval JB; Beuzit L; Pradère B; Thoulouzan M; Khene ZE; Guille F; Rioux-Leclercq N; Mathieu R; Gamé X; Bensalah K; Soulié M; Roumiguié M; Peyronnet B
Urol Int; 2022; 106(2):122-129. PubMed ID: 33626547
[TBL] [Abstract][Full Text] [Related]
23. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy.
Smith ZL; Christodouleas JP; Keefe SM; Malkowicz SB; Guzzo TJ
BJU Int; 2013 Jul; 112(1):13-25. PubMed ID: 23356411
[TBL] [Abstract][Full Text] [Related]
24. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder.
Gakis G; Efstathiou J; Lerner SP; Cookson MS; Keegan KA; Guru KA; Shipley WU; Heidenreich A; Schoenberg MP; Sagaloswky AI; Soloway MS; Stenzl A;
Eur Urol; 2013 Jan; 63(1):45-57. PubMed ID: 22917985
[TBL] [Abstract][Full Text] [Related]
25. Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle invasive bladder cancer.
Maarouf AM; Khalil S; Salem EA; ElAdl M; Nawar N; Zaiton F
BJU Int; 2011 May; 107(10):1605-10. PubMed ID: 20825396
[TBL] [Abstract][Full Text] [Related]
26. Clinically node-positive bladder cancer: oncological results of induction chemotherapy and consolidative surgery.
Stanik M; Poprach A; Macik D; Capak I; Maluskova D; Mareckova N; Lakomy R; Jarkovsky J; Dolezel J
Neoplasma; 2018; 65(2):287-291. PubMed ID: 29534590
[TBL] [Abstract][Full Text] [Related]
27. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer.
Yoshida S; Koga F; Kobayashi S; Ishii C; Tanaka H; Tanaka H; Komai Y; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e21-7. PubMed ID: 22414281
[TBL] [Abstract][Full Text] [Related]
28. Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Yabana T
Urol Oncol; 2021 Feb; 39(2):132.e1-132.e6. PubMed ID: 32792215
[TBL] [Abstract][Full Text] [Related]
29. Selective bladder preservation with curative intent for muscle-invasive bladder cancer: a contemporary review.
Koga F; Kihara K
Int J Urol; 2012 May; 19(5):388-401. PubMed ID: 22409269
[TBL] [Abstract][Full Text] [Related]
30. [OUTCOME OF BLADDER PRESERVATION USING LOW DOSE CHEMORADIATION THERAPY IN PATIENTS WITH LOCALLY INVASIVE BLADDER CANCER].
Matsushita M; Kitakaze H; Okada K; Minato N; Mori N; Yoshioka T
Nihon Hinyokika Gakkai Zasshi; 2018; 109(2):59-67. PubMed ID: 31006743
[TBL] [Abstract][Full Text] [Related]
31. Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer.
Ebbing J; Heckmann RC; Collins JW; Miller K; Erber B; Friedersdorff F; Fuller TF; Busch J; Seifert HH; Ardelt P; Wetterauer C; Hosseini A; Jentzmik F; Kempkensteffen C
Sci Rep; 2018 May; 8(1):8360. PubMed ID: 29849039
[TBL] [Abstract][Full Text] [Related]
32. Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.
Tanaka H; Yoshida S; Koga F; Toda K; Yoshimura R; Nakajima Y; Sugawara E; Akashi T; Waseda Y; Inoue M; Kijima T; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1408-1416. PubMed ID: 29960059
[TBL] [Abstract][Full Text] [Related]
33. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
34. Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle-invasive bladder cancer.
Kang NW; Feng YH; Lin KL; Chen YC; Ho CH; Yang CC
Cancer Med; 2024 Jan; 13(2):e6972. PubMed ID: 38379322
[TBL] [Abstract][Full Text] [Related]
35. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233.
Mak RH; Hunt D; Shipley WU; Efstathiou JA; Tester WJ; Hagan MP; Kaufman DS; Heney NM; Zietman AL
J Clin Oncol; 2014 Dec; 32(34):3801-9. PubMed ID: 25366678
[TBL] [Abstract][Full Text] [Related]
36. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
Kulkarni GS; Hermanns T; Wei Y; Bhindi B; Satkunasivam R; Athanasopoulos P; Bostrom PJ; Kuk C; Li K; Templeton AJ; Sridhar SS; van der Kwast TH; Chung P; Bristow RG; Milosevic M; Warde P; Fleshner NE; Jewett MAS; Bashir S; Zlotta AR
J Clin Oncol; 2017 Jul; 35(20):2299-2305. PubMed ID: 28410011
[TBL] [Abstract][Full Text] [Related]
37. Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy.
Huddart RA; Birtle A; Maynard L; Beresford M; Blazeby J; Donovan J; Kelly JD; Kirkbank T; McLaren DB; Mead G; Moynihan C; Persad R; Scrase C; Lewis R; Hall E
BJU Int; 2017 Nov; 120(5):639-650. PubMed ID: 28453896
[TBL] [Abstract][Full Text] [Related]
38. Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Ham WS; Park JS; Jang WS; Kim J
Ann Surg Oncol; 2024 Feb; 31(2):1384-1392. PubMed ID: 37884699
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
Orré M; Latorzeff I; Fléchon A; Roubaud G; Brouste V; Gaston R; Piéchaud T; Richaud P; Chapet O; Sargos P
PLoS One; 2017; 12(4):e0174978. PubMed ID: 28384195
[TBL] [Abstract][Full Text] [Related]
40. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.
Riesterer O; Ademaj A; Puric E; Eberle B; Beck M; Gomez S; Marder D; Oberacker E; Rogers S; Hälg RA; Kern T; Schwenne S; Stein J; Stutz E; Timm O; Zschaeck S; Weyland MS; Veltsista PD; Wyler S; Wust P; Scheidegger S; Bodis S; Ghadjar P
Int J Hyperthermia; 2022; 39(1):1078-1087. PubMed ID: 35993234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]